Huaren Pharmaceutical Co., Ltd. (SHE:300110)
China flag China · Delayed Price · Currency is CNY
2.610
-0.070 (-2.61%)
Nov 13, 2026, 3:04 PM CST

Huaren Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
-490.57-462.9-1,368188.06180.78130.4
Depreciation & Amortization
107.23107.23118.36126.85149.59134.94
Other Amortization
9.469.468.578.5511.0216.45
Loss (Gain) From Sale of Assets
-0.01-0.01-0.02-4.35-13.86-0.11
Asset Writedown & Restructuring Costs
53153187.577.036.690.28
Loss (Gain) From Sale of Investments
-2.34-2.34-0.36-0.841.390.87
Provision & Write-off of Bad Debts
9.369.369.86-48.2138.6642.19
Other Operating Activities
-9.1291.521,412130.7375.7111.27
Change in Accounts Receivable
51.6351.63172.599.02135.83-1,307
Change in Inventory
56.2656.269.11-58.038.62-2.18
Change in Accounts Payable
15.8115.81-108.13-63.84-361.01303.49
Operating Cash Flow
261.93390.23322.36305.6217.98-578.52
Operating Cash Flow Growth
-10.79%21.05%5.49%40.19%--

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-19.98-48.98-24.69-45.86-42.33-27.86
Sale of Property, Plant & Equipment
0.030.020.0310.0326.430.07
Cash Acquisitions
---13.67-61.61-128-431.8
Divestitures
-1.71----
Investment in Securities
000.06---
Other Investing Activities
0.360.360.360.30.091.01
Investing Cash Flow
-19.59-46.89-37.92-97.14-143.81-458.58

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Short-Term Debt Issued
-90----
Long-Term Debt Issued
-538.85843.331,4982,0101,995
Total Debt Issued
865.15628.85843.331,4982,0101,995
Short-Term Debt Repaid
--90----
Long-Term Debt Repaid
--885.7-1,130-1,606-2,179-694
Lease Payments
-0.46-0.46-0.45---
Total Debt Repaid
-1,074-975.7-1,130-1,606-2,179-694
Net Debt Issued (Repaid)
-208.71-346.86-286.24-108.26-169.121,301
Common Dividends Paid
-33.14-42.46-78.9-86.15-89.38-71.38
Other Financing Activities
-5.14-5.48-4.3773.69105.84-189.23
Financing Cash Flow
-246.99-394.8-369.5-120.72-152.671,040

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-000-0-0-0.02
Net Cash Flow
-4.67-51.45-85.0787.74-78.53.03

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
241.95341.25297.67259.74175.65-606.38
Free Cash Flow Growth
-3.02%14.64%14.60%47.87%--
Free Cash Flow Margin
19.85%25.82%22.00%15.87%10.85%-38.85%
Free Cash Flow Per Share
0.200.290.250.220.15-0.51
Levered Free Cash Flow
34.28364.551,632293.17143.72-634.17
Unlevered Free Cash Flow
57.36390.781,666331.61183.82-594.71
Free Cash Flow After Leases
241.49340.8297.22259.74175.65-606.38

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
123.06119.12138.89183.31146.47183.03
Change in Working Capital
106.9106.955.04-102.22-231.97-1,015